Skip to content
Calculator
Evidence: LowAntibody, not a peptide Clinical Trials Pipeline & In-Development

Trevogrumab

also known as: REGN1033, SAR391786

⚠ Monoclonal antibody — not a classical peptide. A Regeneron anti-myostatin fully human IgG (~150 kDa) being tested as a muscle-sparing adjunct to GLP-1 therapy — CONVERGE combination program with semaglutide in obesity; earlier sarcopenia programs were deprioritized in favor of the obesity opportunity. Included here because it's widely discussed alongside peptides in muscle-sparing conversations.

A fully human monoclonal antibody developed by Regeneron that binds and neutralizes myostatin (GDF-8), reviving prior Phase 2 sarcopenia work within a new "muscle-sparing adjunct to GLP-1" positioning following the success of bimagrumab's BELIEVE Phase 2b combination with semaglutide.

Mechanism of action

Binds myostatin (GDF-8) in circulation, preventing engagement with ActRIIB receptors on skeletal muscle and releasing the myostatin-mediated brake on muscle protein synthesis. Unlike receptor-blockers such as bimagrumab, trevogrumab is a ligand-specific neutralizer — potentially avoiding the off-target effects associated with broader ActRII receptor blockade (BMP9/BMP10 pathway).

Primary uses

  • Muscle preservation during GLP-1 therapy (Phase 2 / CONVERGE program)
  • Historical: sarcopenia (deprioritized)

Typical dosing

not disclosed mg/kg monthly (trial protocols) (intravenous or subcutaneous)

Phase 2 dosing regimens not publicly disclosed in detail.

Regulatory status

Not approved. Regeneron is developing trevogrumab within the CONVERGE program as an adjunct to GLP-1 obesity therapy (paired with semaglutide and/or Regeneron's internal GLP-1 candidate), aiming to preserve lean mass during weight loss. Earlier development in sarcopenia did not advance to approval.

Status as of this entry's last review, April 19, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.

What the studies show

Trevogrumab (REGN1033, SAR391786) is Regeneron's monoclonal antibody against myostatin, a protein rather than a peptide. Its registered trials run from 2012 to 2019; no result is stated here because none is in a paper this site has read.

Registry · 2012

Single ascending doses

Safety and tolerability in 76 healthy volunteers, completed in November 2012.

NCT01507402 · ClinicalTrials.gov record

Registry · 2012

Multiple ascending doses

Safety and tolerability in 60 healthy volunteers, completed in June 2013.

NCT01720576 · ClinicalTrials.gov record

Registry · 2013

Sarcopenia

A phase 2 trial of safety and efficacy in 253 patients with sarcopenia, completed in January 2015.

NCT01963598 · ClinicalTrials.gov record

Registry · 2016

With REGN2477

A phase 1 study of REGN2477 alone and combined with trevogrumab in 82 healthy volunteers, completed in April 2019.

NCT02943239 · ClinicalTrials.gov record

Registry · 2019

Inclusion body myositis

A phase 2 trial of REGN2477 with trevogrumab in sporadic inclusion body myositis, withdrawn before enrolling anyone.

NCT03710941 · ClinicalTrials.gov record

References

  1. [manufacturer] Regeneron Pharmaceuticals. "Pipeline update: CONVERGE muscle-sparing program," investor presentation 2025–2026.
  2. [clinical-trial] ClinicalTrials.gov identifier for Regeneron trevogrumab combination trials in obesity.
  3. [clinicaltrials] ClinicalTrials.gov NCT01507402: "A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)" Regeneron Pharmaceuticals. Phase 1, completed, January 2012 to November 2012 (primary completion), 76 participants. Registry record read October 2, 2026.
  4. [clinicaltrials] ClinicalTrials.gov NCT01720576: "Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)" Regeneron Pharmaceuticals. Phase 1, completed, October 2012 to June 2013 (primary completion), 60 participants. Registry record read October 2, 2026.
  5. [clinicaltrials] ClinicalTrials.gov NCT01963598: "Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia" Regeneron Pharmaceuticals. Phase 2, completed, November 2013 to January 2015 (primary completion), 253 participants. Registry record read October 2, 2026.
  6. [clinicaltrials] ClinicalTrials.gov NCT02943239: "Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men" Regeneron Pharmaceuticals. Phase 1, completed, December 2016 to April 2019 (primary completion), 82 participants. Registry record read October 2, 2026.
  7. [clinicaltrials] ClinicalTrials.gov NCT03710941: "Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis" Regeneron Pharmaceuticals. Phase 2, withdrawn, February 2019 to August 2020 (primary completion), 0 participants. Registry record read October 2, 2026.

Related peptides

Guides & tools

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.